Effectiveness and safety of a mumps containing vaccine in preventing laboratory-confirmed mumps cases from 2002 to 2017: A meta-analysis
Related Experiment Video
Updated: Jul 1, 2025
Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
Published on: February 22, 2019
Bu-Gang Gao1, Ling-Feng Huang2,3, Ping Xie1
1Rehabilitation Teaching and Research Office, Department of Medicine, ChuZhou City Vocational College, Chuzhou, Anhui Province, China.
Abstract:
Emerging evidence has figured that serum conversion rate of mumps is a crucial link of mumps disease. Nevertheless, a rising number of mumps outbreaks caused our attention and studies examining the serum conversion cases were conducted in small samples previously; this meta-analysis was conducted to assess the immunogenicity and safety of a mumps containing vaccine (MuCV) before 2019. We identified a total of 17 studies from the year of 2002-2017. In the case-control studies, the vaccine effectiveness (VE) of MuCV in preventing laboratory-confirmed mumps was 68% (odds risk: 0.32; 95% confidence interval [CI], 0.14-0.70) while in the cohort studies and randomised control trials, 58% (relative risk [RR]: 0.42; 95% CI, 0.26-0.69). Similar intervals of effectiveness rates were found during non-outbreak periods compared with outbreak periods (VE: 66%; RR: 0.34; 95% CI, 0.18-0.68 versus VE: 49%; RR: 0.51; 95% CI, 0.21-1.27). In addition, the MuCV group with two and three doses did not show enhanced laboratory-confirmed mumps than one dose (VE: 58%; RR: 0.42; 95% CI, 0.20-0.88 versus VE: 65%, RR: 0.35; 95% CI, 0.20-0.61) for the reason of the overlap of 95% CI. MuCV had comparable effectiveness comparing non-outbreak and outbreak period, one dose, and two or three doses. MuCV displayed acceptable adverse event profiles.
Insights
This meta-analysis shows mumps-containing vaccines (MuCV) are 68% effective against laboratory-confirmed mumps. Effectiveness remains consistent during outbreaks and across different vaccination schedules, with acceptable safety profiles.
Area of Science:
- Immunology
- Vaccinology
- Epidemiology
Background:
- Mumps outbreaks highlight the need to understand vaccine effectiveness.
- Previous studies on mumps-containing vaccine (MuCV) immunogenicity were limited by small sample sizes.
- Serum conversion rates are critical in mumps disease pathogenesis.
Purpose of the Study:
- To assess the immunogenicity and safety of mumps-containing vaccines (MuCV) using a meta-analysis.
- To evaluate MuCV effectiveness in preventing laboratory-confirmed mumps before 2019.
Main Methods:
- A meta-analysis of 17 studies published between 2002 and 2017.
- Inclusion of case-control, cohort, and randomized controlled trial study designs.
- Analysis of vaccine effectiveness (VE) and safety data.
Main Results:
- MuCV demonstrated a 68% VE in case-control studies (OR: 0.32; 95% CI, 0.14-0.70) and 58% VE in cohort/RCTs (RR: 0.42; 95% CI, 0.26-0.69).
- Comparable effectiveness was observed during outbreak (49% VE; RR: 0.51) and non-outbreak periods (66% VE; RR: 0.34).
- One dose of MuCV showed similar effectiveness to two or three doses (58% VE; RR: 0.42 vs. 65% VE; RR: 0.35), with acceptable adverse event profiles.
Conclusions:
- Mumps-containing vaccines (MuCV) exhibit comparable effectiveness during outbreak and non-outbreak periods.
- Single-dose and multi-dose MuCV regimens show similar efficacy.
- MuCV is a safe and effective option for mumps prevention.
More Related Videos
07:32Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus MRSA Infection
Published on: September 1, 2023
08:52Use of an Influenza Antigen Microarray to Measure the Breadth of Serum Antibodies Across Virus Subtypes
Published on: July 26, 2019
